Navigation Links
iPierian Closes $22 Million Series B Financing Led By Google Ventures
Date:7/8/2010

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing.  The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures.  All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. This financing will allow the company to drive its programs into the clinic, while securing pharmaceutical partnerships.  The Series B financing brings the total amount of equity capital raised by iPierian to $54 million since its inception in 2007.

Krishna Yeshwant, M.D., a partner at Google Ventures, will join the iPierian Board of Directors.  "iPierian's work with iPSCs is incredibly exciting.  The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases," said Dr. Yeshwant.  "The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will dramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission."

Corey Goodman, Ph.D., chairman of the iPierian Board, commented, "We are pleased to welcome our new investors.  Our rapid scientific progress is allowing us to harness iPS technology as a research platform to identify novel therapeutics for patients with major unmet medical needs."

In conjunction with the closing of the Series B financing, Michael C. Venuti, Ph.D., president and chief scientific officer since February 2010, will assume the role of chief executive officer, and will join the Board of Directors. John P. Walker, who has been the CEO of iPierian since February 2009, is stepping down for personal reasons from his position as CEO and member of the Board of Directors and will remain employed by the company as a senior advisor.

"We thank John for his inspired leadership, and I personally value John's continued input as a senior advisor," said Dr. Venuti.  "Under his leadership, the company has emerged as the leader in utilizing the iPSC platform for drug discovery, as evidenced by industrializing the technology, the significant progress with three proprietary programs, and recently being awarded research grants from the California Institute for Regenerative Medicine (CIRM) and the National Institutes of Health (NIH)."

Mr. Walker added, "I am confident in handing over the day-to-day responsibilities of the company to Mike.  He has demonstrated an enviable track record in drug discovery, management and business development, all of which will be important in building on the excitement of this paradigm shift in drug discovery."

For additional information about Dr. Krishna Yeshwant and Google Ventures, please visit www.google.com/ventures.  

About iPierian

iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.  

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute and The University of California, San Francisco.  Our scientific founders are George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, and Deepak Srivastava, M.D., of the Gladstone Institute and UCSF. 

iPierian is located in South San Francisco, California.  For more information, please visit www.ipierian.com.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
4. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
5. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
6. Curemark Closes Series A Financing
7. Blue Belt Technologies, Inc. Closes Series A Financing
8. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
9. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
10. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
11. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
(Date:5/24/2016)...  Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... new role, Marziani will lead the company,s business development and sales team, exploring new ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/27/2016)... , ... May 27, 2016 , ... This campaign aims ... stroke, which we as a society can control and change. , As nearly 795,000 ... every 40 seconds within the United States. Plus, with an estimated 129,000 of these ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... interest stories, courtesy of leaders in the nursing and health care industry. It ... leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
Breaking Medicine News(10 mins):